Famous Patents
British merchant Peter Durand invented the tin can in 1810.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8173136 | Attenuated recombinant newcastle disease virus and vaccine containing the same The present invention relates to a recombinant vector for transcription of the Newcastle disease virus (NDV) genome, a strain of attenuated recombinant NDV with a surface antigen of pathogenic NDV prepared by the vector, a method of preparing a recombinant NDV havin... | 05/08/2012 |
| 8168200 | Vaccine against african horse sickness virus The present invention provides vectors that contain and express in vivo the genes encoding VP2 and VP5 of African Horse Sickness Virus or an epitope thereof that elicits an immune response in a horse against African horse sickness virus, compositions comprising said... | 05/01/2012 |
| 8163293 | Modified Vaccinia Virus Ankara for the vaccination of neonates The invention concerns the use of a virus for the preparation of a medicament for the vaccination or treatment of a neonatal or prenatal animal, including a human, wherein the virus is capable of infecting the cells of the neonatal or prenatal animal, including a hu... | 04/24/2012 |
| 8163292 | Herpes simplex viruses and methods of viral replication A herpes simplex virus is disclosed in which the herpes simplex virus genome comprises a nucleic acid sequence encoding an ING4 polypeptide. ... | 04/24/2012 |
| 8158130 | Method for the preparation of virus-like particles (VLPS) comprising heterologous multiple membrane spanning proteins Enveloped virus vectors are described which comprise a cellular virus receptor protein and which are capable of fusing with a cell which comprises a viral envelope protein to which the cellular virus receptor protein is cognate. Enveloped virus vectors comprising a ... | 04/17/2012 |
| 8088391 | West nile virus vaccine The invention provides chimeric flavivirus vaccines against West Nile virus and methods of using these vaccines to prevent or treat West Nile virus infection. ... | 01/03/2012 |
| 8052977 | DNA vaccine for Koi herpes virus (KHV) disease The present invention provides a DNA vaccine for carps for inducing protective immunity against Koi herpesvirus (KHV). The DNA vaccine comprises a DNA comprising a nucleotide sequence encoding an immunogenic polypeptide against Koi herpesvirus (KHV) of carps, or an ... | 11/08/2011 |
| 8048427 | Subgenomic replicons of the flavivirus dengue The present invention discloses the construction of dengue virus subgenomic replicons containing large deletions in the structural region (C-preM-E) of the genome, which replicons are useful as vaccines to protect against dengue virus infection. ... | 11/01/2011 |
| 8034354 | Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (MVA) The present invention relates to novel insertion sites useful for the integration of exogenous sequences into the Modified Vaccinia Ankara (MVA) virus genome. The present invention further provides plasmid vectors to insert exogenous DNA into the genome of MVA. Furt... | 10/11/2011 |
| 8029800 | Recombinant modified vaccinia virus ankara (MVA) comprising human immunodeficiency virus (HIV) genes inserted into one or more intergenic regions (IGRs) The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives. ... | 10/04/2011 |
| 8021669 | Methods for inducing an immune response in a host comprising administering modified vaccinia virus ankara (MVA) recombinants comprising human immunodeficiency virus (HIV) genes inserted into one or more intergenic regions (IGRs) The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives. ... | 09/20/2011 |
| 8017130 | Method of accelerated vaccination against Ebola viruses The present invention relates to genetic vaccines for stimulating cellular and humoral immune responses in humans and other hosts, and, in particular, relates to recombinant viruses that express heterologous antigens of pathogenic viruses, in single dose form. ... | 09/13/2011 |
| 8012490 | Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents The present invention relates to the engineering of recombinant influenza viruses that express tumor-associated antigens. Expression of tumor-associated antigens by these viruses can be achieved by engineering specific epitopes into influenza virus proteins, or by e... | 09/06/2011 |
| 8012489 | Recombinant vesicular stomatitis virus vaccines for viral hemorrhagic fevers Recombinant VSV viral particles and the use thereof as vaccines for immunization are described. ... | 09/06/2011 |
| 7998488 | Vaccine formulations and uses thereof A liquid or liquid-frozen composition comprising: a modified vaccinia Ankara (MVA) virus or variant or derivative thereof and mannitol, wherein mannitol is the sole stabilization agent of the composition. The mannitol may provide a stabilizing effect at 0 to +10° C... | 08/16/2011 |
| 7994146 | Method of enhancing an immune response A method of enhancing an immune response to an antigen is provided. The method involves augmenting the level of a TAP molecule in a target cell bearing the antigen. Preferably, the TAP molecules enhanced by administering a nucleic acid sequence encoding a TAP-1 and/... | 08/09/2011 |
| 7972605 | Modified vaccinia ankara virus vaccine The present invention relates, in general, to vaccines and, in particular, to a modified vaccinia Ankara (MVA) virus, to a composition comprising such a virus and to methods of using same to induce an immune response. ... | 07/05/2011 |
| 7943144 | Herpes simplex virus complex There is provided an HSV Complex which comprises an avirulent HSV and a targeting agent which allows the HSV particle to infect and lyse a specific targeted cell. The inventors have found a way in which avirulent HSV can be targeted to disease cells, e.g. cancer cel... | 05/17/2011 |
| 7910110 | Bacteriophage-mediated immunisation against hepatitis The present invention relates to vaccines comprising a bacteriophage which has been engineered to express an immunogenic protein/peptide and wherein the surface of the bacteriophage has not been modified to contain proteins/peptides designed to target the phage to r... | 03/22/2011 |
| 7850977 | Promoterless cassettes for expression of alphavirus structural proteins The present invention provides an isolated RNA molecule comprising: a) an alphavirus 5′ replication recognition sequence, wherein at least one initiation codon has been removed from the 5′ replication recognition sequence; b) a nucleotide sequence encoding an al... | 12/14/2010 |
| 7846454 | Cloned genomes of infectious hepatitis C viruses and uses thereof The present invention discloses nucleic acid sequences which encode infectious hepatitis C viruses and the use of these sequences, and polypeptides encoded by all or part of these sequences, in the development of vaccines and diagnostics for HCV and in the developme... | 12/07/2010 |
| 7815913 | Chimeric tymovirus-like particles and process thereof The present disclosure relates to chimeric tymovirus-like particles (TVLPs) comprising a fusion protein that further comprises of a first protein that is a truncated tymovirus coat protein and a second protein. These chimeric TVLPs are useful as antigens. The presen... | 10/19/2010 |
| 7790177 | Immunizing compositions comprising recombinant attenuated self-replicating viral RNA replicons encoding an epitope obtained from the HIV-1 matrix protein myrstate binding site The present invention relates to an immunogenic composition. More particularly, the present invention is a composition directed to eliciting an immune response to at least one covalent binding site of myristate (SEQ ID NOS: 1-3) on the HIV matrix protein. The presen... | 09/07/2010 |
| 7785602 | Recombinant porcine adenovirus vector This invention relates to a recombinant vector including a recombinant porcine adenovirus, stably incorporating and capable of expression of at least one heterologous nucleotide sequence. The nucleotide sequence is preferably one which encodes an antigenic determina... | 08/31/2010 |
| 7771729 | Methods of potentiating HIV-1-specific CD8+ immune responses involving the concomitant administration of DNA and ALVAC expression vectors This invention relates to improved methods of inducing an immune response for the prevention or treatment of HIV-1 infection by using a nucleic acid vaccine in conjunction with a recombinant viral vaccine, e.g., a poxvirus vaccine, to potentiate and broaden the immu... | 08/10/2010 |
| 7767209 | Modified vaccinia virus Ankara (MVA) mutant and use thereof The present invention is directed to a MVA mutant and its use in the immunotherapy and vaccination against numerous diseases, in particular in the prevention and therapy of cancer and infectious diseases. ... | 08/03/2010 |
| 7763258 | Virus-like particles (VLPs) comprising heterologous multiple membrane spanning proteins Enveloped virus vectors are described which comprise a cellular virus receptor protein and which are capable of fusing with a cell which comprises a viral envelope protein to which the cellular virus receptor protein is cognate. Enveloped virus vectors comprising a ... | 07/27/2010 |
| 7758865 | Circovirus sequences associated with piglet weight loss disease (PWD) The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods f... | 07/20/2010 |
| 7754221 | Microorganisms for therapy Therapeutic methods and microorganisms therefor are provided. The microorganisms are designed to accumulate in immunoprivileged tissues and cells, such as in tumors and other proliferating tissue and in inflamed tissues, compared to other tissues, cells and organs, ... | 07/13/2010 |
| 7744900 | Enhancement of the immune response for vaccine and gene therapy applications Expression cassettes are provided comprising a promoter operably linked to a nucleic acid molecule which, when transcribed in vivo, forms double-stranded RNA that induces the production of interferon. Expression cassettes also are provided comprising a promoter oper... | 06/29/2010 |
| 7744899 | Recombinant herpes simplex virus useful for treating neoplastic disease Recombinant herpes simplex viruses comprising DNA encoding cytokines and methods for treating neoplastic diseases using the inventive recombinant viruses are disclosed. ... | 06/29/2010 |
| 7740863 | Recombinant vaccine against West Nile Virus An immunogenic or vaccine composition to induce an immune response or protective immune response against West Nile virus (WNV) in an animal susceptible to WNV. The composition includes a pharmaceutically or veterinarily acceptable vehicle or excipient, and a vector.... | 06/22/2010 |
| 7731974 | Mutant vesicular stomatitis viruses and uses thereof The present invention provides mutant viruses with a decreased ability to block nuclear transport of mRNA or protein in an infected cell which are attenuated in vivo. The mutant viruses of the present invention may also be capable of triggering the anti-viral system... | 06/08/2010 |
| 7700114 | Modified HPV E6 and E7 genes and proteins useful for vaccination Described are DNA sequences encoding an E6 or E7 fusion protein of HPV, wherein said DNA sequences are characterized by a combination of the following features: original codons are exchanged by codons which lead to an enhanced translation in a mammalian cell, they c... | 04/20/2010 |
| 7666433 | Recombinant RSV strains with altered G protein The construction of recombinant respiratory syncytial virus (RSV) strains deleted of the region of G protein most likely to induce unwanted type 2 T cell responses in susceptible recipients is disclosed. Using reverse genetics, recombinant RSV strains were engineere... | 02/23/2010 |
| 7662394 | Nucleic acids encoding chimeric immunogens comprising the Japanese encephalitis virus (JEV) PRM signal sequence The present invention encompasses isolated nucleic acids containing transcriptional units which encode a signal sequence of one flavivirus and an immunogenic flavivirus antigen of a second flavivirus or of a chimeric immunogenic flavivirus | 02/16/2010 |
| 7662395 | Method of enhancing a targeted immune response against tumors The present invention is a composition of recombinant virus which has incorporated into its genome or portion thereof a gene encoding an antigen to a disease causing agent and a recombinant virus which has incorporated into its genome or portion thereof a gene encod... | 02/16/2010 |
| 7638132 | Highly safe smallpox vaccine virus and vaccinia virus vector Objects of the present invention are to generate vaccine strains that undergo reversion (atavism) with difficulty and to provide smallpox vaccines with higher safety. The vaccine viruses are deficient in a part or the whole of the B5R gene of a vaccinia viral strain... | 12/29/2009 |
| 7635485 | Method of accelerated vaccination against Ebola viruses The present invention relates to genetic vaccines for stimulating cellular and humoral immune responses in humans and other hosts, and, in particular, relates to recombinant viruses that express heterologous antigens of pathogenic viruses, in single dose form. ... | 12/22/2009 |
| 7632508 | Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines Chimeric human-bovine parainfluenza viruses (PIVs) are infectious and attenuated in humans and other mammals and useful individually or in combination in vaccine formulations for eliciting an immune response to PIV or other pathogens. Also provided are isolated poly... | 12/15/2009 |
